STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
Globe Newswire8-03-2023, 18:00
Experts Explain Why It's Important for Businesses to Invest 13-02-2023, 04:01